#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cytosine DNA methylation ( 5-methylcytosine ; 5mC , CDM ) is one of the most well-studied epigenomic marks and mechanistically understood epigenetic modifications to date .
3-1	17-25	Cytosine	abstract|abstract[5]	new|new[5]	appos|appos	3-5[0_5]|3-5[0_5]
3-2	26-29	DNA	substance|abstract[5]	new|new[5]	coref	5-16
3-3	30-41	methylation	abstract[5]	new[5]	_	_
3-4	42-43	(	_	_	_	_
3-5	44-60	5-methylcytosine	abstract	giv	appos	3-7
3-6	61-62	;	_	_	_	_
3-7	63-66	5mC	abstract	giv	appos	3-9
3-8	67-68	,	_	_	_	_
3-9	69-72	CDM	abstract	giv	coref	5-26[32_0]
3-10	73-74	)	_	_	_	_
3-11	75-77	is	_	_	_	_
3-12	78-81	one	abstract[9]	new[9]	_	_
3-13	82-84	of	abstract[9]	new[9]	_	_
3-14	85-88	the	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-15	89-93	most	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-16	94-106	well-studied	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-17	107-117	epigenomic	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-18	118-123	marks	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-19	124-127	and	_	_	_	_
3-20	128-143	mechanistically	_	_	_	_
3-21	144-154	understood	_	_	_	_
3-22	155-165	epigenetic	abstract[11]	new[11]	ana	4-1[0_11]
3-23	166-179	modifications	abstract[11]	new[11]	_	_
3-24	180-182	to	abstract[11]	new[11]	_	_
3-25	183-187	date	abstract[11]|time	new[11]|new	_	_
3-26	188-189	.	_	_	_	_

#Text=It plays important roles in various biological processes , including X-chromosome inactivation , genomic imprinting , transposon suppression and transcriptional regulation .
4-1	190-192	It	abstract	giv	_	_
4-2	193-198	plays	_	_	_	_
4-3	199-208	important	abstract[14]	new[14]	_	_
4-4	209-214	roles	abstract[14]	new[14]	_	_
4-5	215-217	in	abstract[14]	new[14]	_	_
4-6	218-225	various	abstract[14]|abstract[15]	new[14]|new[15]	coref	19-21[161_15]
4-7	226-236	biological	abstract[14]|abstract[15]	new[14]|new[15]	_	_
4-8	237-246	processes	abstract[14]|abstract[15]	new[14]|new[15]	_	_
4-9	247-248	,	abstract[14]	new[14]	_	_
4-10	249-258	including	abstract[14]	new[14]	_	_
4-11	259-271	X-chromosome	abstract[14]|event[16]	new[14]|new[16]	_	_
4-12	272-284	inactivation	abstract[14]|event[16]	new[14]|new[16]	_	_
4-13	285-286	,	abstract[14]	new[14]	_	_
4-14	287-294	genomic	abstract[14]|abstract[17]	new[14]|new[17]	_	_
4-15	295-305	imprinting	abstract[14]|abstract[17]	new[14]|new[17]	_	_
4-16	306-307	,	abstract[14]	new[14]	_	_
4-17	308-318	transposon	abstract[14]|time|event[19]	new[14]|new|new[19]	_	_
4-18	319-330	suppression	abstract[14]|event[19]	new[14]|new[19]	_	_
4-19	331-334	and	abstract[14]	new[14]	_	_
4-20	335-350	transcriptional	abstract[14]|abstract[20]	new[14]|new[20]	_	_
4-21	351-361	regulation	abstract[14]|abstract[20]	new[14]|new[20]	_	_
4-22	362-363	.	_	_	_	_

#Text=Technological improvements and dramatic cost reductions for whole-genome sodium bisulfite sequencing ( WGBS ) of DNA have opened the door to the quantitative measurement of DNA methylation at a single base resolution , with datasets now available from numerous species .
5-1	364-377	Technological	abstract[21]	new[21]	_	_
5-2	378-390	improvements	abstract[21]	new[21]	_	_
5-3	391-394	and	_	_	_	_
5-4	395-403	dramatic	abstract[23]	new[23]	_	_
5-5	404-408	cost	quantity|abstract[23]	new|new[23]	_	_
5-6	409-419	reductions	abstract[23]	new[23]	_	_
5-7	420-423	for	abstract[23]	new[23]	_	_
5-8	424-436	whole-genome	abstract[23]|abstract[26]	new[23]|new[26]	coref	11-23[0_26]
5-9	437-443	sodium	abstract[23]|substance|abstract[26]	new[23]|new|new[26]	_	_
5-10	444-453	bisulfite	abstract[23]|abstract|abstract[26]	new[23]|new|new[26]	coref	11-22
5-11	454-464	sequencing	abstract[23]|abstract[26]	new[23]|new[26]	_	_
5-12	465-466	(	_	_	_	_
5-13	467-471	WGBS	object	new	_	_
5-14	472-473	)	_	_	_	_
5-15	474-476	of	_	_	_	_
5-16	477-480	DNA	abstract	giv	coref	5-26
5-17	481-485	have	_	_	_	_
5-18	486-492	opened	_	_	_	_
5-19	493-496	the	object[29]	new[29]	_	_
5-20	497-501	door	object[29]	new[29]	_	_
5-21	502-504	to	_	_	_	_
5-22	505-508	the	abstract[30]	new[30]	_	_
5-23	509-521	quantitative	abstract[30]	new[30]	_	_
5-24	522-533	measurement	abstract[30]	new[30]	_	_
5-25	534-536	of	abstract[30]	new[30]	_	_
5-26	537-540	DNA	abstract[30]|abstract|abstract[32]	new[30]|giv|giv[32]	coref|coref|coref|coref	6-5[0_32]|7-3|6-5[0_32]|7-3
5-27	541-552	methylation	abstract[30]|abstract[32]	new[30]|giv[32]	_	_
5-28	553-555	at	abstract[30]|abstract[32]	new[30]|giv[32]	_	_
5-29	556-557	a	abstract[30]|abstract[32]|abstract[34]	new[30]|giv[32]|new[34]	coref	15-21[114_34]
5-30	558-564	single	abstract[30]|abstract[32]|abstract[34]	new[30]|giv[32]|new[34]	_	_
5-31	565-569	base	abstract[30]|abstract[32]|place|abstract[34]	new[30]|giv[32]|new|new[34]	_	_
5-32	570-580	resolution	abstract[30]|abstract[32]|abstract[34]	new[30]|giv[32]|new[34]	_	_
5-33	581-582	,	_	_	_	_
5-34	583-587	with	_	_	_	_
5-35	588-596	datasets	abstract[35]	new[35]	_	_
5-36	597-600	now	abstract[35]	new[35]	_	_
5-37	601-610	available	abstract[35]	new[35]	_	_
5-38	611-615	from	_	_	_	_
5-39	616-624	numerous	animal[36]	new[36]	_	_
5-40	625-632	species	animal[36]	new[36]	_	_
5-41	633-634	.	_	_	_	_

#Text=In humans , significant methylation differences are observed in the white blood cells of matched monozygotic and dizygotic twins , and significant intra- and inter-population differential methylation has been identified in a study of three human populations ( Caucasian-American , African-American and Chinese-American ) .
6-1	635-637	In	_	_	_	_
6-2	638-644	humans	person	new	_	_
6-3	645-646	,	_	_	_	_
6-4	647-658	significant	abstract[39]	new[39]	_	_
6-5	659-670	methylation	abstract|abstract[39]	giv|new[39]	coref	6-22[44_0]
6-6	671-682	differences	abstract[39]	new[39]	_	_
6-7	683-686	are	_	_	_	_
6-8	687-695	observed	_	_	_	_
6-9	696-698	in	_	_	_	_
6-10	699-702	the	object[41]	new[41]	_	_
6-11	703-708	white	object[41]	new[41]	_	_
6-12	709-714	blood	substance|object[41]	new|new[41]	_	_
6-13	715-720	cells	object[41]	new[41]	_	_
6-14	721-723	of	object[41]	new[41]	_	_
6-15	724-731	matched	object[41]|substance[42]	new[41]|new[42]	_	_
6-16	732-743	monozygotic	object[41]|substance[42]	new[41]|new[42]	_	_
6-17	744-747	and	object[41]	new[41]	_	_
6-18	748-757	dizygotic	object[41]|person[43]	new[41]|new[43]	_	_
6-19	758-763	twins	object[41]|person[43]	new[41]|new[43]	_	_
6-20	764-765	,	_	_	_	_
6-21	766-769	and	_	_	_	_
6-22	770-781	significant	abstract[44]	giv[44]	coref	7-4[0_44]
6-23	782-788	intra-	abstract[44]	giv[44]	_	_
6-24	789-792	and	abstract[44]	giv[44]	_	_
6-25	793-809	inter-population	abstract[44]	giv[44]	_	_
6-26	810-822	differential	abstract[44]	giv[44]	_	_
6-27	823-834	methylation	abstract[44]	giv[44]	_	_
6-28	835-838	has	_	_	_	_
6-29	839-843	been	_	_	_	_
6-30	844-854	identified	_	_	_	_
6-31	855-857	in	_	_	_	_
6-32	858-859	a	abstract[45]	new[45]	_	_
6-33	860-865	study	abstract[45]	new[45]	_	_
6-34	866-868	of	abstract[45]	new[45]	_	_
6-35	869-874	three	abstract[45]|person[46]	new[45]|new[46]	appos	6-39[47_46]
6-36	875-880	human	abstract[45]|person[46]	new[45]|new[46]	_	_
6-37	881-892	populations	abstract[45]|person[46]	new[45]|new[46]	_	_
6-38	893-894	(	_	_	_	_
6-39	895-913	Caucasian-American	person[47]	giv[47]	coref	20-13[172_47]
6-40	914-915	,	person[47]	giv[47]	_	_
6-41	916-932	African-American	person[47]	giv[47]	_	_
6-42	933-936	and	person[47]	giv[47]	_	_
6-43	937-953	Chinese-American	person[47]	giv[47]	_	_
6-44	954-955	)	_	_	_	_
6-45	956-957	.	_	_	_	_

#Text=Likewise , DNA methylation levels vary considerably in samples experiencing changes during development or in response to environmental change .
7-1	958-966	Likewise	_	_	_	_
7-2	967-968	,	_	_	_	_
7-3	969-972	DNA	abstract|abstract[50]	giv|new[50]	coref|coref	8-6|8-6
7-4	973-984	methylation	abstract|abstract[50]	giv|new[50]	coref	8-6[59_0]
7-5	985-991	levels	abstract[50]	new[50]	_	_
7-6	992-996	vary	_	_	_	_
7-7	997-1009	considerably	_	_	_	_
7-8	1010-1012	in	_	_	_	_
7-9	1013-1020	samples	object	new	coref	19-14
7-10	1021-1033	experiencing	_	_	_	_
7-11	1034-1041	changes	abstract[52]	new[52]	coref	20-6[171_52]
7-12	1042-1048	during	abstract[52]	new[52]	_	_
7-13	1049-1060	development	abstract[52]|abstract	new[52]|new	coref	10-12[72_0]
7-14	1061-1063	or	_	_	_	_
7-15	1064-1066	in	_	_	_	_
7-16	1067-1075	response	abstract[54]	new[54]	_	_
7-17	1076-1078	to	abstract[54]	new[54]	_	_
7-18	1079-1092	environmental	abstract[54]|abstract[55]	new[54]|new[55]	coref	15-34[118_55]
7-19	1093-1099	change	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-20	1100-1101	.	_	_	_	_

#Text=Translation of the advances in DNA methylation to clinical and personalized medical contexts has been proposed .
8-1	1102-1113	Translation	abstract[56]	new[56]	_	_
8-2	1114-1116	of	abstract[56]	new[56]	_	_
8-3	1117-1120	the	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-4	1121-1129	advances	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-5	1130-1132	in	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-6	1133-1136	DNA	abstract[56]|abstract[57]|abstract|abstract[59]	new[56]|new[57]|giv|giv[59]	coref|coref|coref|coref	9-15[0_59]|19-24|9-15[0_59]|19-24
8-7	1137-1148	methylation	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|giv[59]	_	_
8-8	1149-1151	to	abstract[56]	new[56]	_	_
8-9	1152-1160	clinical	abstract[56]|abstract[60]	new[56]|new[60]	_	_
8-10	1161-1164	and	abstract[56]|abstract[60]	new[56]|new[60]	_	_
8-11	1165-1177	personalized	abstract[56]|abstract[60]	new[56]|new[60]	_	_
8-12	1178-1185	medical	abstract[56]|abstract[60]	new[56]|new[60]	_	_
8-13	1186-1194	contexts	abstract[56]|abstract[60]	new[56]|new[60]	_	_
8-14	1195-1198	has	_	_	_	_
8-15	1199-1203	been	_	_	_	_
8-16	1204-1212	proposed	_	_	_	_
8-17	1213-1214	.	_	_	_	_

#Text=Evidence of epigenetic alterations induced by disease emphasizes the significant potential value of high-resolution methylation pattern analysis .
9-1	1215-1223	Evidence	abstract[61]	new[61]	_	_
9-2	1224-1226	of	abstract[61]	new[61]	_	_
9-3	1227-1237	epigenetic	abstract[61]|abstract|abstract[63]	new[61]|new|new[63]	coref|coref|coref|coref	10-25|10-24[76_63]|10-25|10-24[76_63]
9-4	1238-1249	alterations	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-5	1250-1257	induced	_	_	_	_
9-6	1258-1260	by	_	_	_	_
9-7	1261-1268	disease	abstract	new	coref	10-29[77_0]
9-8	1269-1279	emphasizes	_	_	_	_
9-9	1280-1283	the	abstract[65]	new[65]	coref	27-12[228_65]
9-10	1284-1295	significant	abstract[65]	new[65]	_	_
9-11	1296-1305	potential	abstract[65]	new[65]	_	_
9-12	1306-1311	value	abstract[65]	new[65]	_	_
9-13	1312-1314	of	abstract[65]	new[65]	_	_
9-14	1315-1330	high-resolution	abstract[65]|abstract[68]	new[65]|new[68]	_	_
9-15	1331-1342	methylation	abstract[65]|abstract|abstract[68]	new[65]|giv|new[68]	coref	11-12
9-16	1343-1350	pattern	abstract[65]|abstract|abstract[68]	new[65]|new|new[68]	_	_
9-17	1351-1359	analysis	abstract[65]|abstract[68]	new[65]|new[68]	_	_
9-18	1360-1361	.	_	_	_	_

#Text=However , proper translation of this knowledge for diagnostics depends upon the development of genome-wide techniques for the rapid and robust identification of specific epigenetic alterations associated with the disease .
10-1	1362-1369	However	_	_	_	_
10-2	1370-1371	,	_	_	_	_
10-3	1372-1378	proper	abstract[69]	new[69]	_	_
10-4	1379-1390	translation	abstract[69]	new[69]	_	_
10-5	1391-1393	of	abstract[69]	new[69]	_	_
10-6	1394-1398	this	abstract[69]|abstract[70]	new[69]|new[70]	_	_
10-7	1399-1408	knowledge	abstract[69]|abstract[70]	new[69]|new[70]	_	_
10-8	1409-1412	for	abstract[69]|abstract[70]	new[69]|new[70]	_	_
10-9	1413-1424	diagnostics	abstract[69]|abstract[70]|abstract	new[69]|new[70]|new	coref	16-46[130_0]
10-10	1425-1432	depends	_	_	_	_
10-11	1433-1437	upon	_	_	_	_
10-12	1438-1441	the	abstract[72]	giv[72]	coref	23-35[198_72]
10-13	1442-1453	development	abstract[72]	giv[72]	_	_
10-14	1454-1456	of	abstract[72]	giv[72]	_	_
10-15	1457-1468	genome-wide	abstract[72]|abstract[73]	giv[72]|new[73]	_	_
10-16	1469-1479	techniques	abstract[72]|abstract[73]	giv[72]|new[73]	_	_
10-17	1480-1483	for	abstract[72]|abstract[73]	giv[72]|new[73]	_	_
10-18	1484-1487	the	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-19	1488-1493	rapid	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-20	1494-1497	and	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-21	1498-1504	robust	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-22	1505-1519	identification	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-23	1520-1522	of	abstract[72]|abstract[73]|abstract[74]	giv[72]|new[73]|new[74]	_	_
10-24	1523-1531	specific	abstract[72]|abstract[73]|abstract[74]|abstract[76]	giv[72]|new[73]|new[74]|giv[76]	_	_
10-25	1532-1542	epigenetic	abstract[72]|abstract[73]|abstract[74]|abstract|abstract[76]	giv[72]|new[73]|new[74]|giv|giv[76]	_	_
10-26	1543-1554	alterations	abstract[72]|abstract[73]|abstract[74]|abstract[76]	giv[72]|new[73]|new[74]|giv[76]	_	_
10-27	1555-1565	associated	_	_	_	_
10-28	1566-1570	with	_	_	_	_
10-29	1571-1574	the	abstract[77]	giv[77]	coref	16-24[124_77]
10-30	1575-1582	disease	abstract[77]	giv[77]	_	_
10-31	1583-1584	.	_	_	_	_

#Text=Currently , there are numerous available bioinformatics tools to estimate the methylation status of nearly every cytosine position within a whole-genome bisulfite sequencing dataset .
11-1	1585-1594	Currently	_	_	_	_
11-2	1595-1596	,	_	_	_	_
11-3	1597-1602	there	_	_	_	_
11-4	1603-1606	are	_	_	_	_
11-5	1607-1615	numerous	object[79]	new[79]	coref	12-1[86_79]
11-6	1616-1625	available	object[79]	new[79]	_	_
11-7	1626-1640	bioinformatics	abstract|object[79]	new|new[79]	_	_
11-8	1641-1646	tools	object[79]	new[79]	_	_
11-9	1647-1649	to	_	_	_	_
11-10	1650-1658	estimate	_	_	_	_
11-11	1659-1662	the	abstract[81]	new[81]	_	_
11-12	1663-1674	methylation	abstract|abstract[81]	giv|new[81]	coref	15-35
11-13	1675-1681	status	abstract[81]	new[81]	_	_
11-14	1682-1684	of	abstract[81]	new[81]	_	_
11-15	1685-1691	nearly	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-16	1692-1697	every	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-17	1698-1706	cytosine	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-18	1707-1715	position	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-19	1716-1722	within	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-20	1723-1724	a	abstract[81]|abstract[82]|object[85]	new[81]|new[82]|new[85]	_	_
11-21	1725-1737	whole-genome	abstract[81]|abstract[82]|object[85]	new[81]|new[82]|new[85]	_	_
11-22	1738-1747	bisulfite	abstract[81]|abstract[82]|abstract|object[85]	new[81]|new[82]|giv|new[85]	_	_
11-23	1748-1758	sequencing	abstract[81]|abstract[82]|abstract|object[85]	new[81]|new[82]|giv|new[85]	_	_
11-24	1759-1766	dataset	abstract[81]|abstract[82]|object[85]	new[81]|new[82]|new[85]	_	_
11-25	1767-1768	.	_	_	_	_

#Text=These tools are generally supported by an application of robust statistical approaches ; DSS , BiSeq , and methylKit , among others , are ones that apply generalized linear regression ( beta-regression ) in the estimation of differentially methylated positions ( DMPs ) .
12-1	1769-1774	These	object[86]	giv[86]	_	_
12-2	1775-1780	tools	object[86]	giv[86]	_	_
12-3	1781-1784	are	_	_	_	_
12-4	1785-1794	generally	_	_	_	_
12-5	1795-1804	supported	_	_	_	_
12-6	1805-1807	by	_	_	_	_
12-7	1808-1810	an	abstract[87]	new[87]	coref	18-18[148_87]
12-8	1811-1822	application	abstract[87]	new[87]	_	_
12-9	1823-1825	of	abstract[87]	new[87]	_	_
12-10	1826-1832	robust	abstract[87]|abstract[88]	new[87]|new[88]	coref	15-1[107_88]
12-11	1833-1844	statistical	abstract[87]|abstract[88]	new[87]|new[88]	_	_
12-12	1845-1855	approaches	abstract[87]|abstract[88]	new[87]|new[88]	_	_
12-13	1856-1857	;	_	_	_	_
12-14	1858-1861	DSS	abstract	new	_	_
12-15	1862-1863	,	_	_	_	_
12-16	1864-1869	BiSeq	object	new	_	_
12-17	1870-1871	,	_	_	_	_
12-18	1872-1875	and	_	_	_	_
12-19	1876-1885	methylKit	object	new	coref	13-4
12-20	1886-1887	,	_	_	_	_
12-21	1888-1893	among	_	_	_	_
12-22	1894-1900	others	_	_	_	_
12-23	1901-1902	,	_	_	_	_
12-24	1903-1906	are	_	_	_	_
12-25	1907-1911	ones	object	new	_	_
12-26	1912-1916	that	_	_	_	_
12-27	1917-1922	apply	_	_	_	_
12-28	1923-1934	generalized	abstract[93]	new[93]	appos	12-32[0_93]
12-29	1935-1941	linear	abstract[93]	new[93]	_	_
12-30	1942-1952	regression	abstract[93]	new[93]	_	_
12-31	1953-1954	(	_	_	_	_
12-32	1955-1970	beta-regression	abstract	giv	_	_
12-33	1971-1972	)	_	_	_	_
12-34	1973-1975	in	_	_	_	_
12-35	1976-1979	the	abstract[95]	new[95]	coref	14-5[103_95]
12-36	1980-1990	estimation	abstract[95]	new[95]	_	_
12-37	1991-1993	of	abstract[95]	new[95]	_	_
12-38	1994-2008	differentially	abstract[95]|abstract[96]	new[95]|new[96]	appos	12-42[0_96]
12-39	2009-2019	methylated	abstract[95]|abstract[96]	new[95]|new[96]	_	_
12-40	2020-2029	positions	abstract[95]|abstract[96]	new[95]|new[96]	_	_
12-41	2030-2031	(	_	_	_	_
12-42	2032-2036	DMPs	abstract	giv	ana	15-17
12-43	2037-2038	)	_	_	_	_
12-44	2039-2040	.	_	_	_	_

#Text=In addition , methylKit provides the option to apply Fisher ’s exact test .
13-1	2041-2043	In	_	_	_	_
13-2	2044-2052	addition	_	_	_	_
13-3	2053-2054	,	_	_	_	_
13-4	2055-2064	methylKit	object	giv	_	_
13-5	2065-2073	provides	_	_	_	_
13-6	2074-2077	the	abstract[99]	new[99]	_	_
13-7	2078-2084	option	abstract[99]	new[99]	_	_
13-8	2085-2087	to	_	_	_	_
13-9	2088-2093	apply	_	_	_	_
13-10	2094-2100	Fisher	person[100]|abstract[101]	new[100]|new[101]	ana|ana	14-5[0_101]|14-5[0_101]
13-11	2101-2103	’s	person[100]|abstract[101]	new[100]|new[101]	_	_
13-12	2104-2109	exact	abstract[101]	new[101]	_	_
13-13	2110-2114	test	abstract[101]	new[101]	_	_
13-14	2115-2116	.	_	_	_	_

#Text=Alternatively , methylpy bases its estimation on the implementation of the root-mean-square test ( RMST ) .
14-1	2117-2130	Alternatively	_	_	_	_
14-2	2131-2132	,	_	_	_	_
14-3	2133-2141	methylpy	_	_	_	_
14-4	2142-2147	bases	_	_	_	_
14-5	2148-2151	its	abstract|abstract[103]	giv|giv[103]	coref|coref	14-11[105_0]|14-11[105_0]
14-6	2152-2162	estimation	abstract[103]	giv[103]	_	_
14-7	2163-2165	on	abstract[103]	giv[103]	_	_
14-8	2166-2169	the	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
14-9	2170-2184	implementation	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
14-10	2185-2187	of	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
14-11	2188-2191	the	abstract[103]|abstract[104]|abstract[105]	giv[103]|new[104]|giv[105]	appos	14-15[0_105]
14-12	2192-2208	root-mean-square	abstract[103]|abstract[104]|abstract[105]	giv[103]|new[104]|giv[105]	_	_
14-13	2209-2213	test	abstract[103]|abstract[104]|abstract[105]	giv[103]|new[104]|giv[105]	_	_
14-14	2214-2215	(	_	_	_	_
14-15	2216-2220	RMST	abstract	giv	_	_
14-16	2221-2222	)	_	_	_	_
14-17	2223-2224	.	_	_	_	_

#Text=Most of these approaches do not incorporate the influence of natural stochasticity ( randomness ) to their models , limiting their resolution predominantly to genomic regions with the highest probability of having undergone a methylation change .
15-1	2225-2229	Most	abstract[107]	giv[107]	coref	16-5[119_107]
15-2	2230-2232	of	abstract[107]	giv[107]	_	_
15-3	2233-2238	these	abstract[107]	giv[107]	_	_
15-4	2239-2249	approaches	abstract[107]	giv[107]	_	_
15-5	2250-2252	do	_	_	_	_
15-6	2253-2256	not	_	_	_	_
15-7	2257-2268	incorporate	_	_	_	_
15-8	2269-2272	the	abstract[108]	new[108]	_	_
15-9	2273-2282	influence	abstract[108]	new[108]	_	_
15-10	2283-2285	of	abstract[108]	new[108]	_	_
15-11	2286-2293	natural	abstract[108]|abstract[109]	new[108]|new[109]	appos	15-14[0_109]
15-12	2294-2307	stochasticity	abstract[108]|abstract[109]	new[108]|new[109]	_	_
15-13	2308-2309	(	abstract[108]	new[108]	_	_
15-14	2310-2320	randomness	abstract[108]|abstract	new[108]|giv	_	_
15-15	2321-2322	)	abstract[108]	new[108]	_	_
15-16	2323-2325	to	abstract[108]	new[108]	_	_
15-17	2326-2331	their	abstract[108]|abstract|abstract[112]	new[108]|giv|new[112]	ana|ana	15-21|15-21
15-18	2332-2338	models	abstract[108]|abstract[112]	new[108]|new[112]	_	_
15-19	2339-2340	,	_	_	_	_
15-20	2341-2349	limiting	_	_	_	_
15-21	2350-2355	their	abstract|abstract[114]	giv|giv[114]	coref|coref	16-27|16-27
15-22	2356-2366	resolution	abstract[114]	giv[114]	_	_
15-23	2367-2380	predominantly	_	_	_	_
15-24	2381-2383	to	_	_	_	_
15-25	2384-2391	genomic	place[115]	new[115]	_	_
15-26	2392-2399	regions	place[115]	new[115]	_	_
15-27	2400-2404	with	place[115]	new[115]	_	_
15-28	2405-2408	the	place[115]|abstract[116]	new[115]|new[116]	coref	19-1[155_116]
15-29	2409-2416	highest	place[115]|abstract[116]	new[115]|new[116]	_	_
15-30	2417-2428	probability	place[115]|abstract[116]	new[115]|new[116]	_	_
15-31	2429-2431	of	_	_	_	_
15-32	2432-2438	having	_	_	_	_
15-33	2439-2448	undergone	_	_	_	_
15-34	2449-2450	a	abstract[118]	giv[118]	_	_
15-35	2451-2462	methylation	abstract|abstract[118]	giv|giv[118]	coref	17-4
15-36	2463-2469	change	abstract[118]	giv[118]	_	_
15-37	2470-2471	.	_	_	_	_

#Text=As a consequence , these approaches do not have the ability to distinguish the DMP signal associated with a specific treatment ( or disease ) from DMPs deriving from natural variation within control ( or heathy ) individuals , and are thus not suitable for clinical diagnostics .
16-1	2472-2474	As	_	_	_	_
16-2	2475-2476	a	_	_	_	_
16-3	2477-2488	consequence	_	_	_	_
16-4	2489-2490	,	_	_	_	_
16-5	2491-2496	these	abstract[119]	giv[119]	coref	18-30[0_119]
16-6	2497-2507	approaches	abstract[119]	giv[119]	_	_
16-7	2508-2510	do	_	_	_	_
16-8	2511-2514	not	_	_	_	_
16-9	2515-2519	have	_	_	_	_
16-10	2520-2523	the	abstract[120]	new[120]	_	_
16-11	2524-2531	ability	abstract[120]	new[120]	_	_
16-12	2532-2534	to	_	_	_	_
16-13	2535-2546	distinguish	_	_	_	_
16-14	2547-2550	the	abstract[122]	new[122]	coref	19-35[168_122]
16-15	2551-2554	DMP	abstract|abstract[122]	new|new[122]	coref	29-8[252_0]
16-16	2555-2561	signal	abstract[122]	new[122]	_	_
16-17	2562-2572	associated	_	_	_	_
16-18	2573-2577	with	_	_	_	_
16-19	2578-2579	a	abstract[123]	new[123]	coref	19-37[0_123]
16-20	2580-2588	specific	abstract[123]	new[123]	_	_
16-21	2589-2598	treatment	abstract[123]	new[123]	_	_
16-22	2599-2600	(	_	_	_	_
16-23	2601-2603	or	_	_	_	_
16-24	2604-2611	disease	abstract[124]	giv[124]	_	_
16-25	2612-2613	)	abstract[124]	giv[124]	_	_
16-26	2614-2618	from	abstract[124]	giv[124]	_	_
16-27	2619-2623	DMPs	abstract[124]|abstract	giv[124]|giv	coref	22-10
16-28	2624-2632	deriving	_	_	_	_
16-29	2633-2637	from	_	_	_	_
16-30	2638-2645	natural	abstract[126]	new[126]	coref	17-3[133_126]
16-31	2646-2655	variation	abstract[126]	new[126]	_	_
16-32	2656-2662	within	abstract[126]	new[126]	_	_
16-33	2663-2670	control	abstract[126]|abstract	new[126]|new	coref	19-11
16-34	2671-2672	(	abstract[126]	new[126]	_	_
16-35	2673-2675	or	abstract[126]	new[126]	_	_
16-36	2676-2682	heathy	abstract[126]|abstract	new[126]|new	_	_
16-37	2683-2684	)	abstract[126]	new[126]	_	_
16-38	2685-2696	individuals	abstract[126]|person	new[126]|new	coref	17-25[140_0]
16-39	2697-2698	,	_	_	_	_
16-40	2699-2702	and	_	_	_	_
16-41	2703-2706	are	_	_	_	_
16-42	2707-2711	thus	_	_	_	_
16-43	2712-2715	not	_	_	_	_
16-44	2716-2724	suitable	_	_	_	_
16-45	2725-2728	for	_	_	_	_
16-46	2729-2737	clinical	abstract[130]	giv[130]	coref	17-7[0_130]
16-47	2738-2749	diagnostics	abstract[130]	giv[130]	_	_
16-48	2750-2751	.	_	_	_	_

#Text=We suggest that methylation variation in diagnostics is essentially a signal detection problem , equivalent to a binary classification problem for discriminating healthy versus diseased individuals .
17-1	2752-2754	We	person	acc	ana	29-1
17-2	2755-2762	suggest	_	_	_	_
17-3	2763-2767	that	abstract[133]	giv[133]	coref	17-9[135_133]
17-4	2768-2779	methylation	abstract|abstract[133]	giv|giv[133]	coref	19-4[156_0]
17-5	2780-2789	variation	abstract[133]	giv[133]	_	_
17-6	2790-2792	in	abstract[133]	giv[133]	_	_
17-7	2793-2804	diagnostics	abstract[133]|abstract	giv[133]|giv	coref	24-17[203_0]
17-8	2805-2807	is	_	_	_	_
17-9	2808-2819	essentially	abstract[135]	giv[135]	appos	17-12[137_135]
17-10	2820-2821	a	abstract[135]	giv[135]	_	_
17-11	2822-2828	signal	abstract[135]	giv[135]	_	_
17-12	2829-2838	detection	abstract|abstract[137]	new|giv[137]	coref|coref|coref|coref	18-2|19-31[166_137]|18-2|19-31[166_137]
17-13	2839-2846	problem	abstract[137]	giv[137]	_	_
17-14	2847-2848	,	_	_	_	_
17-15	2849-2859	equivalent	_	_	_	_
17-16	2860-2862	to	_	_	_	_
17-17	2863-2864	a	abstract[139]	new[139]	coref	18-10[146_139]
17-18	2865-2871	binary	abstract[139]	new[139]	_	_
17-19	2872-2886	classification	abstract|abstract[139]	new|new[139]	coref	26-14
17-20	2887-2894	problem	abstract[139]	new[139]	_	_
17-21	2895-2898	for	_	_	_	_
17-22	2899-2913	discriminating	_	_	_	_
17-23	2914-2921	healthy	_	_	_	_
17-24	2922-2928	versus	_	_	_	_
17-25	2929-2937	diseased	person[140]	giv[140]	_	_
17-26	2938-2949	individuals	person[140]	giv[140]	_	_
17-27	2950-2951	.	_	_	_	_

#Text=Signal detection theory provides the methodological framework to address this type of detection problem , evidenced in its common application to clinical diagnostic tests , machine-learning ( ML ) approaches , and human communication technologies .
18-1	2952-2958	Signal	person|abstract[143]	new|new[143]	coref|coref	31-10[272_143]|31-10[272_143]
18-2	2959-2968	detection	abstract|abstract[143]	giv|new[143]	coref	18-13
18-3	2969-2975	theory	abstract[143]	new[143]	_	_
18-4	2976-2984	provides	_	_	_	_
18-5	2985-2988	the	abstract[144]	new[144]	_	_
18-6	2989-3003	methodological	abstract[144]	new[144]	_	_
18-7	3004-3013	framework	abstract[144]	new[144]	_	_
18-8	3014-3016	to	_	_	_	_
18-9	3017-3024	address	_	_	_	_
18-10	3025-3029	this	abstract[146]	giv[146]	ana	18-18[0_146]
18-11	3030-3034	type	abstract[146]	giv[146]	_	_
18-12	3035-3037	of	abstract[146]	giv[146]	_	_
18-13	3038-3047	detection	abstract|abstract[146]	giv|giv[146]	coref	26-1
18-14	3048-3055	problem	abstract[146]	giv[146]	_	_
18-15	3056-3057	,	_	_	_	_
18-16	3058-3067	evidenced	_	_	_	_
18-17	3068-3070	in	_	_	_	_
18-18	3071-3074	its	abstract|abstract[148]	giv|giv[148]	_	_
18-19	3075-3081	common	abstract[148]	giv[148]	_	_
18-20	3082-3093	application	abstract[148]	giv[148]	_	_
18-21	3094-3096	to	abstract[148]	giv[148]	_	_
18-22	3097-3105	clinical	abstract[148]|abstract[149]	giv[148]|new[149]	coref	25-26[212_149]
18-23	3106-3116	diagnostic	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
18-24	3117-3122	tests	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
18-25	3123-3124	,	abstract[148]	giv[148]	_	_
18-26	3125-3141	machine-learning	abstract[148]|quantity	giv[148]|new	appos	18-28
18-27	3142-3143	(	abstract[148]	giv[148]	_	_
18-28	3144-3146	ML	abstract[148]|quantity	giv[148]|giv	coref	31-14
18-29	3147-3148	)	abstract[148]	giv[148]	_	_
18-30	3149-3159	approaches	abstract[148]|abstract	giv[148]|giv	coref	25-7[207_0]
18-31	3160-3161	,	abstract[148]	giv[148]	_	_
18-32	3162-3165	and	abstract[148]	giv[148]	_	_
18-33	3166-3171	human	abstract[148]|abstract[154]	giv[148]|new[154]	_	_
18-34	3172-3185	communication	abstract[148]|abstract|abstract[154]	giv[148]|new|new[154]	_	_
18-35	3186-3198	technologies	abstract[148]|abstract[154]	giv[148]|new[154]	_	_
18-36	3199-3200	.	_	_	_	_

#Text=The probability of extreme methylation changes occurring spontaneously in a control group of samples by the stochastic fluctuations inherent to biochemical processes and DNA maintenance , requires the discrimination of this background variation from a biological treatment signal .
19-1	3201-3204	The	abstract[155]	giv[155]	coref	20-16[173_155]
19-2	3205-3216	probability	abstract[155]	giv[155]	_	_
19-3	3217-3219	of	abstract[155]	giv[155]	_	_
19-4	3220-3227	extreme	abstract[155]|abstract[156]	giv[155]|giv[156]	coref	20-8[0_156]
19-5	3228-3239	methylation	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
19-6	3240-3247	changes	_	_	_	_
19-7	3248-3257	occurring	_	_	_	_
19-8	3258-3271	spontaneously	_	_	_	_
19-9	3272-3274	in	_	_	_	_
19-10	3275-3276	a	abstract[158]	new[158]	coref	30-32[266_158]
19-11	3277-3284	control	abstract|abstract[158]	giv|new[158]	coref	29-19
19-12	3285-3290	group	abstract[158]	new[158]	_	_
19-13	3291-3293	of	abstract[158]	new[158]	_	_
19-14	3294-3301	samples	abstract[158]|object	new[158]|giv	_	_
19-15	3302-3304	by	_	_	_	_
19-16	3305-3308	the	abstract[160]	new[160]	coref	21-1[176_160]
19-17	3309-3319	stochastic	abstract[160]	new[160]	_	_
19-18	3320-3332	fluctuations	abstract[160]	new[160]	_	_
19-19	3333-3341	inherent	abstract[160]	new[160]	_	_
19-20	3342-3344	to	_	_	_	_
19-21	3345-3356	biochemical	abstract[161]	giv[161]	coref	21-7[177_161]
19-22	3357-3366	processes	abstract[161]	giv[161]	_	_
19-23	3367-3370	and	abstract[161]	giv[161]	_	_
19-24	3371-3374	DNA	abstract[161]|abstract|abstract[163]	giv[161]|giv|new[163]	coref|coref	28-6|28-6
19-25	3375-3386	maintenance	abstract[161]|abstract[163]	giv[161]|new[163]	_	_
19-26	3387-3388	,	_	_	_	_
19-27	3389-3397	requires	_	_	_	_
19-28	3398-3401	the	abstract[164]	new[164]	_	_
19-29	3402-3416	discrimination	abstract[164]	new[164]	_	_
19-30	3417-3419	of	abstract[164]	new[164]	_	_
19-31	3420-3424	this	abstract[164]|abstract[166]	new[164]|giv[166]	coref	21-12[179_166]
19-32	3425-3435	background	abstract[164]|abstract|abstract[166]	new[164]|new|giv[166]	coref	21-13
19-33	3436-3445	variation	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
19-34	3446-3450	from	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
19-35	3451-3452	a	abstract[164]|abstract[166]|abstract[168]	new[164]|giv[166]|giv[168]	coref	25-7[0_168]
19-36	3453-3463	biological	abstract[164]|abstract[166]|abstract[168]	new[164]|giv[166]|giv[168]	_	_
19-37	3464-3473	treatment	abstract[164]|abstract[166]|abstract|abstract[168]	new[164]|giv[166]|giv|giv[168]	coref	30-34
19-38	3474-3480	signal	abstract[164]|abstract[166]|abstract[168]	new[164]|giv[166]|giv[168]	_	_
19-39	3481-3482	.	_	_	_	_

#Text=Regardless of environmental constancy , statistically significant methylation changes are found in control populations with probability greater than zero .
20-1	3483-3493	Regardless	_	_	_	_
20-2	3494-3496	of	_	_	_	_
20-3	3497-3510	environmental	abstract[169]	new[169]	_	_
20-4	3511-3520	constancy	abstract[169]	new[169]	_	_
20-5	3521-3522	,	_	_	_	_
20-6	3523-3536	statistically	abstract[171]	giv[171]	coref	30-16[262_171]
20-7	3537-3548	significant	abstract[171]	giv[171]	_	_
20-8	3549-3560	methylation	abstract|abstract[171]	giv|giv[171]	coref	22-20
20-9	3561-3568	changes	abstract[171]	giv[171]	_	_
20-10	3569-3572	are	_	_	_	_
20-11	3573-3578	found	_	_	_	_
20-12	3579-3581	in	_	_	_	_
20-13	3582-3589	control	person[172]	giv[172]	coref	22-14[185_172]
20-14	3590-3601	populations	person[172]	giv[172]	_	_
20-15	3602-3606	with	person[172]	giv[172]	_	_
20-16	3607-3618	probability	person[172]|abstract[173]	giv[172]|giv[173]	ana	22-4[0_173]
20-17	3619-3626	greater	person[172]|abstract[173]	giv[172]|giv[173]	_	_
20-18	3627-3631	than	_	_	_	_
20-19	3632-3636	zero	quantity	new	_	_
20-20	3637-3638	.	_	_	_	_

#Text=These system fluctuations , inherent in biological stochastic processes , comprise natural background variation detected in human methylomes .
21-1	3639-3644	These	abstract[176]	giv[176]	coref	23-22[195_176]
21-2	3645-3651	system	abstract|abstract[176]	new|giv[176]	_	_
21-3	3652-3664	fluctuations	abstract[176]	giv[176]	_	_
21-4	3665-3666	,	abstract[176]	giv[176]	_	_
21-5	3667-3675	inherent	abstract[176]	giv[176]	_	_
21-6	3676-3678	in	_	_	_	_
21-7	3679-3689	biological	abstract[177]	giv[177]	_	_
21-8	3690-3700	stochastic	abstract[177]	giv[177]	_	_
21-9	3701-3710	processes	abstract[177]	giv[177]	_	_
21-10	3711-3712	,	_	_	_	_
21-11	3713-3721	comprise	_	_	_	_
21-12	3722-3729	natural	abstract[179]	giv[179]	coref	24-1[199_179]
21-13	3730-3740	background	abstract|abstract[179]	giv|giv[179]	coref	28-19
21-14	3741-3750	variation	abstract[179]	giv[179]	_	_
21-15	3751-3759	detected	_	_	_	_
21-16	3760-3762	in	_	_	_	_
21-17	3763-3768	human	object[180]	new[180]	_	_
21-18	3769-3779	methylomes	object[180]	new[180]	_	_
21-19	3780-3781	.	_	_	_	_

#Text=By simulation , it is feasible to demonstrate that DMPs spontaneously arise in control populations , and that regulatory methylation signals also occur naturally in the control group .
22-1	3782-3784	By	_	_	_	_
22-2	3785-3795	simulation	abstract	new	coref	32-15
22-3	3796-3797	,	_	_	_	_
22-4	3798-3800	it	abstract	giv	coref	29-25[257_0]
22-5	3801-3803	is	_	_	_	_
22-6	3804-3812	feasible	_	_	_	_
22-7	3813-3815	to	person[183]	new[183]	_	_
22-8	3816-3827	demonstrate	person[183]	new[183]	_	_
22-9	3828-3832	that	person[183]	new[183]	_	_
22-10	3833-3837	DMPs	person[183]|abstract	new[183]|giv	coref	30-11
22-11	3838-3851	spontaneously	person[183]	new[183]	_	_
22-12	3852-3857	arise	person[183]	new[183]	_	_
22-13	3858-3860	in	_	_	_	_
22-14	3861-3868	control	person[185]	giv[185]	coref	28-9[244_185]
22-15	3869-3880	populations	person[185]	giv[185]	_	_
22-16	3881-3882	,	_	_	_	_
22-17	3883-3886	and	_	_	_	_
22-18	3887-3891	that	_	_	_	_
22-19	3892-3902	regulatory	abstract[187]	new[187]	_	_
22-20	3903-3914	methylation	abstract|abstract[187]	giv|new[187]	coref	23-5
22-21	3915-3922	signals	abstract[187]	new[187]	_	_
22-22	3923-3927	also	_	_	_	_
22-23	3928-3933	occur	_	_	_	_
22-24	3934-3943	naturally	_	_	_	_
22-25	3944-3946	in	_	_	_	_
22-26	3947-3950	the	person[188]	new[188]	_	_
22-27	3951-3958	control	person[188]	new[188]	_	_
22-28	3959-3964	group	person[188]	new[188]	_	_
22-29	3965-3966	.	_	_	_	_

#Text=Stochastic fluctuation of the methylation process is expected , since methylation regulatory machinery participates , not only in organismal adaptation to micro- and macro-environmental fluctuations , but also in transitions across different stages of organismal ontogenetic development .
23-1	3967-3977	Stochastic	abstract[189]	new[189]	_	_
23-2	3978-3989	fluctuation	abstract[189]	new[189]	_	_
23-3	3990-3992	of	abstract[189]	new[189]	_	_
23-4	3993-3996	the	abstract[189]|abstract[191]	new[189]|new[191]	_	_
23-5	3997-4008	methylation	abstract[189]|abstract|abstract[191]	new[189]|giv|new[191]	coref	23-11
23-6	4009-4016	process	abstract[189]|abstract[191]	new[189]|new[191]	_	_
23-7	4017-4019	is	_	_	_	_
23-8	4020-4028	expected	_	_	_	_
23-9	4029-4030	,	_	_	_	_
23-10	4031-4036	since	_	_	_	_
23-11	4037-4048	methylation	abstract|abstract[193]	giv|new[193]	coref|coref	24-11|24-11
23-12	4049-4059	regulatory	abstract[193]	new[193]	_	_
23-13	4060-4069	machinery	abstract[193]	new[193]	_	_
23-14	4070-4082	participates	_	_	_	_
23-15	4083-4084	,	_	_	_	_
23-16	4085-4088	not	_	_	_	_
23-17	4089-4093	only	abstract[194]	new[194]	_	_
23-18	4094-4096	in	abstract[194]	new[194]	_	_
23-19	4097-4107	organismal	abstract[194]	new[194]	_	_
23-20	4108-4118	adaptation	abstract[194]	new[194]	_	_
23-21	4119-4121	to	abstract[194]	new[194]	_	_
23-22	4122-4128	micro-	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
23-23	4129-4132	and	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
23-24	4133-4152	macro-environmental	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
23-25	4153-4165	fluctuations	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
23-26	4166-4167	,	_	_	_	_
23-27	4168-4171	but	_	_	_	_
23-28	4172-4176	also	_	_	_	_
23-29	4177-4179	in	_	_	_	_
23-30	4180-4191	transitions	event[196]	new[196]	_	_
23-31	4192-4198	across	event[196]	new[196]	_	_
23-32	4199-4208	different	event[196]|abstract[197]	new[196]|new[197]	_	_
23-33	4209-4215	stages	event[196]|abstract[197]	new[196]|new[197]	_	_
23-34	4216-4218	of	event[196]|abstract[197]	new[196]|new[197]	_	_
23-35	4219-4229	organismal	event[196]|abstract[197]|abstract[198]	new[196]|new[197]|giv[198]	_	_
23-36	4230-4241	ontogenetic	event[196]|abstract[197]|abstract[198]	new[196]|new[197]|giv[198]	_	_
23-37	4242-4253	development	event[196]|abstract[197]|abstract[198]	new[196]|new[197]|giv[198]	_	_
23-38	4254-4255	.	_	_	_	_

#Text=This variation must be factored into the construction of a methylation pipeline to be used in clinical diagnostics .
24-1	4256-4260	This	abstract[199]	giv[199]	coref	28-1[241_199]
24-2	4261-4270	variation	abstract[199]	giv[199]	_	_
24-3	4271-4275	must	_	_	_	_
24-4	4276-4278	be	_	_	_	_
24-5	4279-4287	factored	_	_	_	_
24-6	4288-4292	into	_	_	_	_
24-7	4293-4296	the	abstract[200]	new[200]	_	_
24-8	4297-4309	construction	abstract[200]	new[200]	_	_
24-9	4310-4312	of	abstract[200]	new[200]	_	_
24-10	4313-4314	a	abstract[200]|object[202]	new[200]|new[202]	_	_
24-11	4315-4326	methylation	abstract[200]|abstract|object[202]	new[200]|giv|new[202]	coref	28-6[243_0]
24-12	4327-4335	pipeline	abstract[200]|object[202]	new[200]|new[202]	_	_
24-13	4336-4338	to	_	_	_	_
24-14	4339-4341	be	_	_	_	_
24-15	4342-4346	used	_	_	_	_
24-16	4347-4349	in	_	_	_	_
24-17	4350-4358	clinical	abstract[203]	giv[203]	coref	25-11[0_203]
24-18	4359-4370	diagnostics	abstract[203]	giv[203]	_	_
24-19	4371-4372	.	_	_	_	_

#Text=The need for the application of signal detection-based approaches in diagnostics was pointed out decades ago , and is standard practice in current implementations of clinical diagnostic tests .
25-1	4373-4376	The	abstract[204]	new[204]	_	_
25-2	4377-4381	need	abstract[204]	new[204]	_	_
25-3	4382-4385	for	abstract[204]	new[204]	_	_
25-4	4386-4389	the	abstract[204]|abstract[205]	new[204]|new[205]	_	_
25-5	4390-4401	application	abstract[204]|abstract[205]	new[204]|new[205]	_	_
25-6	4402-4404	of	abstract[204]|abstract[205]	new[204]|new[205]	_	_
25-7	4405-4411	signal	abstract[204]|abstract[205]|abstract|abstract[207]	new[204]|new[205]|giv|giv[207]	coref|coref|coref|coref	26-1[214_207]|27-14[229_0]|26-1[214_207]|27-14[229_0]
25-8	4412-4427	detection-based	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
25-9	4428-4438	approaches	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
25-10	4439-4441	in	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
25-11	4442-4453	diagnostics	abstract[204]|abstract[205]|abstract[207]|abstract	new[204]|new[205]|giv[207]|giv	coref	32-10[278_0]
25-12	4454-4457	was	_	_	_	_
25-13	4458-4465	pointed	_	_	_	_
25-14	4466-4469	out	_	_	_	_
25-15	4470-4477	decades	time[209]	new[209]	_	_
25-16	4478-4481	ago	time[209]	new[209]	_	_
25-17	4482-4483	,	_	_	_	_
25-18	4484-4487	and	_	_	_	_
25-19	4488-4490	is	_	_	_	_
25-20	4491-4499	standard	abstract[210]	new[210]	_	_
25-21	4500-4508	practice	abstract[210]	new[210]	_	_
25-22	4509-4511	in	abstract[210]	new[210]	_	_
25-23	4512-4519	current	abstract[210]|abstract[211]	new[210]|new[211]	coref	26-12[217_211]
25-24	4520-4535	implementations	abstract[210]|abstract[211]	new[210]|new[211]	_	_
25-25	4536-4538	of	abstract[210]|abstract[211]	new[210]|new[211]	_	_
25-26	4539-4547	clinical	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	coref	32-18[282_212]
25-27	4548-4558	diagnostic	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	_	_
25-28	4559-4564	tests	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	_	_
25-29	4565-4566	.	_	_	_	_

#Text=Detection approaches are , by default , included in machine/statistical learning implementations for classification tasks , since the evaluation of classifier performance is basically a detection problem .
26-1	4567-4576	Detection	abstract|abstract[214]	giv|giv[214]	coref|coref	26-26|26-26
26-2	4577-4587	approaches	abstract[214]	giv[214]	_	_
26-3	4588-4591	are	_	_	_	_
26-4	4592-4593	,	_	_	_	_
26-5	4594-4596	by	_	_	_	_
26-6	4597-4604	default	abstract	new	_	_
26-7	4605-4606	,	_	_	_	_
26-8	4607-4615	included	_	_	_	_
26-9	4616-4618	in	_	_	_	_
26-10	4619-4638	machine/statistical	substance	new	_	_
26-11	4639-4647	learning	_	_	_	_
26-12	4648-4663	implementations	abstract[217]	giv[217]	_	_
26-13	4664-4667	for	abstract[217]	giv[217]	_	_
26-14	4668-4682	classification	abstract[217]|abstract|abstract[219]	giv[217]|giv|new[219]	coref|coref	27-47|27-47
26-15	4683-4688	tasks	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
26-16	4689-4690	,	_	_	_	_
26-17	4691-4696	since	_	_	_	_
26-18	4697-4700	the	abstract[220]	new[220]	coref	26-24[224_220]
26-19	4701-4711	evaluation	abstract[220]	new[220]	_	_
26-20	4712-4714	of	abstract[220]	new[220]	_	_
26-21	4715-4725	classifier	abstract[220]|object|abstract[222]	new[220]|new|new[222]	_	_
26-22	4726-4737	performance	abstract[220]|abstract[222]	new[220]|new[222]	_	_
26-23	4738-4740	is	_	_	_	_
26-24	4741-4750	basically	abstract[224]	giv[224]	coref	27-46[238_224]
26-25	4751-4752	a	abstract[224]	giv[224]	_	_
26-26	4753-4762	detection	abstract|abstract[224]	giv|giv[224]	coref	27-54[240_0]
26-27	4763-4770	problem	abstract[224]	giv[224]	_	_
26-28	4771-4772	.	_	_	_	_

#Text=Thus , the determination of the optimal cutoff ( threshold ) value at which signal can be discriminated from noise at an acceptable signal-to-noise ratio ( i. e. , maximum accuracy and sensitivity , lowest false discovery rate ( FDR ) ) is equivalent to a classification problem , a direct corollary to diagnostic detection .
27-1	4773-4777	Thus	_	_	_	_
27-2	4778-4779	,	_	_	_	_
27-3	4780-4783	the	abstract[225]	new[225]	_	_
27-4	4784-4797	determination	abstract[225]	new[225]	_	_
27-5	4798-4800	of	abstract[225]	new[225]	_	_
27-6	4801-4804	the	abstract[225]|abstract[226]	new[225]|new[226]	appos	27-10[0_226]
27-7	4805-4812	optimal	abstract[225]|abstract[226]	new[225]|new[226]	_	_
27-8	4813-4819	cutoff	abstract[225]|abstract[226]	new[225]|new[226]	_	_
27-9	4820-4821	(	abstract[225]	new[225]	_	_
27-10	4822-4831	threshold	abstract[225]|abstract	new[225]|giv	_	_
27-11	4832-4833	)	abstract[225]	new[225]	_	_
27-12	4834-4839	value	abstract[225]|abstract[228]	new[225]|giv[228]	_	_
27-13	4840-4842	at	abstract[225]|abstract[228]	new[225]|giv[228]	_	_
27-14	4843-4848	which	abstract[225]|abstract[228]|abstract[229]	new[225]|giv[228]|giv[229]	coref	28-15[247_229]
27-15	4849-4855	signal	abstract[225]|abstract[228]|abstract[229]	new[225]|giv[228]|giv[229]	_	_
27-16	4856-4859	can	_	_	_	_
27-17	4860-4862	be	_	_	_	_
27-18	4863-4876	discriminated	_	_	_	_
27-19	4877-4881	from	_	_	_	_
27-20	4882-4887	noise	abstract[230]	new[230]	_	_
27-21	4888-4890	at	abstract[230]	new[230]	_	_
27-22	4891-4893	an	abstract[230]|abstract[231]	new[230]|new[231]	_	_
27-23	4894-4904	acceptable	abstract[230]|abstract[231]	new[230]|new[231]	_	_
27-24	4905-4920	signal-to-noise	abstract[230]|abstract[231]	new[230]|new[231]	_	_
27-25	4921-4926	ratio	abstract[230]|abstract[231]	new[230]|new[231]	_	_
27-26	4927-4928	(	_	_	_	_
27-27	4929-4931	i.	_	_	_	_
27-28	4932-4934	e.	_	_	_	_
27-29	4935-4936	,	_	_	_	_
27-30	4937-4944	maximum	abstract[232]	new[232]	_	_
27-31	4945-4953	accuracy	abstract[232]	new[232]	_	_
27-32	4954-4957	and	_	_	_	_
27-33	4958-4969	sensitivity	abstract	new	_	_
27-34	4970-4971	,	_	_	_	_
27-35	4972-4978	lowest	abstract[235]	new[235]	appos	27-40[0_235]
27-36	4979-4984	false	abstract[235]	new[235]	_	_
27-37	4985-4994	discovery	abstract|abstract[235]	new|new[235]	_	_
27-38	4995-4999	rate	abstract[235]	new[235]	_	_
27-39	5000-5001	(	_	_	_	_
27-40	5002-5005	FDR	abstract	giv	_	_
27-41	5006-5007	)	_	_	_	_
27-42	5008-5009	)	_	_	_	_
27-43	5010-5012	is	_	_	_	_
27-44	5013-5023	equivalent	_	_	_	_
27-45	5024-5026	to	_	_	_	_
27-46	5027-5028	a	abstract[238]	giv[238]	appos	27-50[239_238]
27-47	5029-5043	classification	abstract|abstract[238]	giv|giv[238]	_	_
27-48	5044-5051	problem	abstract[238]	giv[238]	_	_
27-49	5052-5053	,	_	_	_	_
27-50	5054-5055	a	abstract[239]	giv[239]	coref	31-4[268_239]
27-51	5056-5062	direct	abstract[239]	giv[239]	_	_
27-52	5063-5072	corollary	abstract[239]	giv[239]	_	_
27-53	5073-5075	to	abstract[239]	giv[239]	_	_
27-54	5076-5086	diagnostic	abstract[239]|abstract[240]	giv[239]|giv[240]	coref	31-11[0_240]
27-55	5087-5096	detection	abstract[239]|abstract[240]	giv[239]|giv[240]	_	_
27-56	5097-5098	.	_	_	_	_

#Text=The natural spontaneous variation of DNA methylation in human populations complicates the discrimination of the methylation signal from background variation .
28-1	5099-5102	The	abstract[241]	giv[241]	coref	28-19[249_241]
28-2	5103-5110	natural	abstract[241]	giv[241]	_	_
28-3	5111-5122	spontaneous	abstract[241]	giv[241]	_	_
28-4	5123-5132	variation	abstract[241]	giv[241]	_	_
28-5	5133-5135	of	abstract[241]	giv[241]	_	_
28-6	5136-5139	DNA	abstract[241]|abstract|abstract[243]	giv[241]|giv|giv[243]	coref|coref	28-16[0_243]|28-16[0_243]
28-7	5140-5151	methylation	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
28-8	5152-5154	in	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
28-9	5155-5160	human	abstract[241]|abstract[243]|person[244]	giv[241]|giv[243]|giv[244]	_	_
28-10	5161-5172	populations	abstract[241]|abstract[243]|person[244]	giv[241]|giv[243]|giv[244]	_	_
28-11	5173-5184	complicates	_	_	_	_
28-12	5185-5188	the	abstract[245]	new[245]	_	_
28-13	5189-5203	discrimination	abstract[245]	new[245]	_	_
28-14	5204-5206	of	abstract[245]	new[245]	_	_
28-15	5207-5210	the	abstract[245]|abstract[247]	new[245]|giv[247]	coref	31-10[0_247]
28-16	5211-5222	methylation	abstract[245]|abstract|abstract[247]	new[245]|giv|giv[247]	_	_
28-17	5223-5229	signal	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
28-18	5230-5234	from	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
28-19	5235-5245	background	abstract[245]|abstract[247]|abstract|abstract[249]	new[245]|giv[247]|giv|giv[249]	_	_
28-20	5246-5255	variation	abstract[245]|abstract[247]|abstract[249]	new[245]|giv[247]|giv[249]	_	_
28-21	5256-5257	.	_	_	_	_

#Text=We address this issue by determining whether a given DMP detected in the treatment/patient population occurs within the control population as well , and the probability of observing it .
29-1	5258-5260	We	person	giv	ana	31-2
29-2	5261-5268	address	_	_	_	_
29-3	5269-5273	this	abstract[251]	new[251]	_	_
29-4	5274-5279	issue	abstract[251]	new[251]	_	_
29-5	5280-5282	by	_	_	_	_
29-6	5283-5294	determining	_	_	_	_
29-7	5295-5302	whether	_	_	_	_
29-8	5303-5304	a	abstract[252]	giv[252]	_	_
29-9	5305-5310	given	abstract[252]	giv[252]	_	_
29-10	5311-5314	DMP	abstract[252]	giv[252]	_	_
29-11	5315-5323	detected	_	_	_	_
29-12	5324-5326	in	_	_	_	_
29-13	5327-5330	the	abstract[254]	new[254]	_	_
29-14	5331-5348	treatment/patient	person|abstract[254]	new|new[254]	_	_
29-15	5349-5359	population	abstract[254]	new[254]	_	_
29-16	5360-5366	occurs	_	_	_	_
29-17	5367-5373	within	_	_	_	_
29-18	5374-5377	the	person[256]	new[256]	_	_
29-19	5378-5385	control	abstract|person[256]	giv|new[256]	_	_
29-20	5386-5396	population	person[256]	new[256]	_	_
29-21	5397-5399	as	_	_	_	_
29-22	5400-5404	well	_	_	_	_
29-23	5405-5406	,	_	_	_	_
29-24	5407-5410	and	_	_	_	_
29-25	5411-5414	the	abstract[257]	giv[257]	ana	29-29[0_257]
29-26	5415-5426	probability	abstract[257]	giv[257]	_	_
29-27	5427-5429	of	_	_	_	_
29-28	5430-5439	observing	_	_	_	_
29-29	5440-5442	it	abstract	giv	coref	30-22[263_0]
29-30	5443-5444	.	_	_	_	_

#Text=Therefore , the focus is not on the identification of DMPs , but on whether these statistically significant changes occur with high probability ( under the fixed experimental conditions ) in only the treatment group .
30-1	5445-5454	Therefore	_	_	_	_
30-2	5455-5456	,	_	_	_	_
30-3	5457-5460	the	abstract[259]	new[259]	_	_
30-4	5461-5466	focus	abstract[259]	new[259]	_	_
30-5	5467-5469	is	_	_	_	_
30-6	5470-5473	not	_	_	_	_
30-7	5474-5476	on	_	_	_	_
30-8	5477-5480	the	event[260]	new[260]	_	_
30-9	5481-5495	identification	event[260]	new[260]	_	_
30-10	5496-5498	of	event[260]	new[260]	_	_
30-11	5499-5503	DMPs	event[260]|abstract	new[260]|giv	_	_
30-12	5504-5505	,	_	_	_	_
30-13	5506-5509	but	_	_	_	_
30-14	5510-5512	on	_	_	_	_
30-15	5513-5520	whether	_	_	_	_
30-16	5521-5526	these	abstract[262]	giv[262]	_	_
30-17	5527-5540	statistically	abstract[262]	giv[262]	_	_
30-18	5541-5552	significant	abstract[262]	giv[262]	_	_
30-19	5553-5560	changes	abstract[262]	giv[262]	_	_
30-20	5561-5566	occur	_	_	_	_
30-21	5567-5571	with	_	_	_	_
30-22	5572-5576	high	abstract[263]	giv[263]	_	_
30-23	5577-5588	probability	abstract[263]	giv[263]	_	_
30-24	5589-5590	(	abstract[263]	giv[263]	_	_
30-25	5591-5596	under	abstract[263]	giv[263]	_	_
30-26	5597-5600	the	abstract[263]|abstract[264]	giv[263]|new[264]	_	_
30-27	5601-5606	fixed	abstract[263]|abstract[264]	giv[263]|new[264]	_	_
30-28	5607-5619	experimental	abstract[263]|abstract[264]	giv[263]|new[264]	_	_
30-29	5620-5630	conditions	abstract[263]|abstract[264]	giv[263]|new[264]	_	_
30-30	5631-5632	)	abstract[263]	giv[263]	_	_
30-31	5633-5635	in	abstract[263]	giv[263]	_	_
30-32	5636-5640	only	abstract[263]|abstract[266]	giv[263]|giv[266]	_	_
30-33	5641-5644	the	abstract[263]|abstract[266]	giv[263]|giv[266]	_	_
30-34	5645-5654	treatment	abstract[263]|abstract|abstract[266]	giv[263]|giv|giv[266]	_	_
30-35	5655-5660	group	abstract[263]|abstract[266]	giv[263]|giv[266]	_	_
30-36	5661-5662	.	_	_	_	_

#Text=Here we address this problem in the context of signal detection theory and ML frameworks .
31-1	5663-5667	Here	_	_	_	_
31-2	5668-5670	we	person	giv	ana	32-6
31-3	5671-5678	address	_	_	_	_
31-4	5679-5683	this	abstract[268]	giv[268]	_	_
31-5	5684-5691	problem	abstract[268]	giv[268]	_	_
31-6	5692-5694	in	abstract[268]	giv[268]	_	_
31-7	5695-5698	the	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
31-8	5699-5706	context	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
31-9	5707-5709	of	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
31-10	5710-5716	signal	abstract[268]|abstract[269]|abstract|abstract[272]	giv[268]|new[269]|giv|giv[272]	_	_
31-11	5717-5726	detection	abstract[268]|abstract[269]|abstract|abstract[272]	giv[268]|new[269]|giv|giv[272]	_	_
31-12	5727-5733	theory	abstract[268]|abstract[269]|abstract[272]	giv[268]|new[269]|giv[272]	_	_
31-13	5734-5737	and	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
31-14	5738-5740	ML	abstract[268]|abstract[269]|abstract|abstract[274]	giv[268]|new[269]|giv|new[274]	_	_
31-15	5741-5751	frameworks	abstract[268]|abstract[269]|abstract[274]	giv[268]|new[269]|new[274]	_	_
31-16	5752-5753	.	_	_	_	_

#Text=To illustrate the feasibility of our proposed approach in clinical diagnostics , results from simulation studies and tests of two available methylome datasets from leukemia and autism patients are presented and discussed .
32-1	5754-5756	To	_	_	_	_
32-2	5757-5767	illustrate	_	_	_	_
32-3	5768-5771	the	abstract[275]	new[275]	_	_
32-4	5772-5783	feasibility	abstract[275]	new[275]	_	_
32-5	5784-5786	of	abstract[275]	new[275]	_	_
32-6	5787-5790	our	abstract[275]|person|abstract[277]	new[275]|giv|new[277]	coref|coref	33-1[288_277]|33-1[288_277]
32-7	5791-5799	proposed	abstract[275]|abstract[277]	new[275]|new[277]	_	_
32-8	5800-5808	approach	abstract[275]|abstract[277]	new[275]|new[277]	_	_
32-9	5809-5811	in	abstract[275]|abstract[277]	new[275]|new[277]	_	_
32-10	5812-5820	clinical	abstract[275]|abstract[277]|abstract[278]	new[275]|new[277]|giv[278]	_	_
32-11	5821-5832	diagnostics	abstract[275]|abstract[277]|abstract[278]	new[275]|new[277]|giv[278]	_	_
32-12	5833-5834	,	_	_	_	_
32-13	5835-5842	results	abstract[279]	new[279]	_	_
32-14	5843-5847	from	abstract[279]	new[279]	_	_
32-15	5848-5858	simulation	abstract[279]|abstract|event[281]	new[279]|giv|new[281]	_	_
32-16	5859-5866	studies	abstract[279]|event[281]	new[279]|new[281]	_	_
32-17	5867-5870	and	abstract[279]	new[279]	_	_
32-18	5871-5876	tests	abstract[279]|abstract[282]	new[279]|giv[282]	_	_
32-19	5877-5879	of	abstract[279]|abstract[282]	new[279]|giv[282]	_	_
32-20	5880-5883	two	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
32-21	5884-5893	available	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
32-22	5894-5903	methylome	abstract[279]|abstract[282]|abstract|abstract[284]	new[279]|giv[282]|new|new[284]	_	_
32-23	5904-5912	datasets	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
32-24	5913-5917	from	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
32-25	5918-5926	leukemia	abstract[279]|abstract[282]|abstract[284]|abstract	new[279]|giv[282]|new[284]|new	_	_
32-26	5927-5930	and	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
32-27	5931-5937	autism	abstract[279]|abstract[282]|abstract[284]|abstract	new[279]|giv[282]|new[284]|new	_	_
32-28	5938-5946	patients	person	new	_	_
32-29	5947-5950	are	_	_	_	_
32-30	5951-5960	presented	_	_	_	_
32-31	5961-5964	and	_	_	_	_
32-32	5965-5974	discussed	_	_	_	_
32-33	5975-5976	.	_	_	_	_

#Text=This approach is implemented in the R package Methyl-IT , available at GitHub : https://github.com/genomaths/MethylIT .
33-1	5977-5981	This	abstract[288]	giv[288]	_	_
33-2	5982-5990	approach	abstract[288]	giv[288]	_	_
33-3	5991-5993	is	_	_	_	_
33-4	5994-6005	implemented	_	_	_	_
33-5	6006-6008	in	_	_	_	_
33-6	6009-6012	the	object[290]	new[290]	_	_
33-7	6013-6014	R	person|object[290]	new|new[290]	coref	34-2
33-8	6015-6022	package	object[290]	new[290]	_	_
33-9	6023-6032	Methyl-IT	object[290]|event	new[290]|new	_	_
33-10	6033-6034	,	_	_	_	_
33-11	6035-6044	available	_	_	_	_
33-12	6045-6047	at	_	_	_	_
33-13	6048-6054	GitHub	place	new	_	_
33-14	6055-6056	:	_	_	_	_
33-15	6057-6094	https://github.com/genomaths/MethylIT	place	new	_	_
33-16	6095-6096	.	_	_	_	_

#Text=The R scripts to reproduce these analyses are available at the PSU GitLab : https://git.psu.edu/genomath/MethylIT_examples .
34-1	6097-6100	The	abstract[295]	new[295]	_	_
34-2	6101-6102	R	person|abstract[295]	giv|new[295]	_	_
34-3	6103-6110	scripts	abstract[295]	new[295]	_	_
34-4	6111-6113	to	_	_	_	_
34-5	6114-6123	reproduce	_	_	_	_
34-6	6124-6129	these	abstract[296]	new[296]	_	_
34-7	6130-6138	analyses	abstract[296]	new[296]	_	_
34-8	6139-6142	are	_	_	_	_
34-9	6143-6152	available	_	_	_	_
34-10	6153-6155	at	_	_	_	_
34-11	6156-6159	the	abstract[298]	new[298]	_	_
34-12	6160-6163	PSU	abstract|abstract[298]	new|new[298]	_	_
34-13	6164-6170	GitLab	abstract[298]	new[298]	_	_
34-14	6171-6172	:	_	_	_	_
34-15	6173-6219	https://git.psu.edu/genomath/MethylIT_examples	place	new	_	_
34-16	6220-6221	.	_	_	_	_
